After OGAWA's share price hit the daily limit-up for four consecutive trading days, with a cumulative gain of about 46.65%, the company issued an announcement on abnormal stock trading fluctuations, noting that its health service robot-related business is still in an early exploration stage, does not currently involve the humanoid robot field, and as of the announcement disclosure date had not generated sales revenue, so it will not have a material impact on the company's current or near-term operating results. From September 21 to 24, OGAWA's share price hit the daily limit-up for four straight sessions. On September 21 and 22, and again on September 23 and 24, the cumulative deviation in closing price gains over two consecutive trading days exceeded 20%, triggering abnormal fluctuation disclosures, and the company released abnormal fluctuation announcements on the evenings of September 22 and September 27 respectively. After verification and inquiry with its controlling shareholders, the company disclosed that controlling shareholders Zou Jianhan and Li Wuling, along with shareholder Wei Gang, each signed share transfer agreements with Shanghai Yixin Private Fund Management Co., Ltd., planning to transfer a combined 62.3739 million shares, representing approximately 10.000% of the company's total unrestricted tradable shares. The company emphasized that in January 2026 it established a wholly owned subsidiary, Xiamen OGAWA Robot Technology Co., Ltd., to explore scenario-based applications in the vertical health service robot field, and through a fund it invested in embodied intelligence target company Xinghai Tu Beijing Artificial Intelligence Technology Co., Ltd., with a stake of less than 1%. The semi-annual report shows that in the first half of 2026, OGAWA achieved operating revenue of 2.703 billion yuan, up 16.14% year on year, while net profit attributable to shareholders of the listed company was negative 73.924 million yuan, down 373.47% year on year, and non-GAAP net profit was negative 91.5419 million yuan, down 653.35% year on year, mainly affected by foreign exchange losses of 71.7936 million yuan and losses from some non-core businesses. The company also cautioned that as of the close on September 24, 2026, its latest rolling price-to-earnings ratio was negative, while the latest rolling price-to-earnings ratio for the electrical machinery and equipment manufacturing industry was 20.67 times, a significant difference between the two.
Xiamen Comfort Science&Technology Group Co LtdOGAWA's health service robot business is still in early exploration, has no sales revenue, and does not involve humanoid robots, so the robot theme driving its limit-ups lacks near-term substance.
Shanghai Yixin signed agreements to acquire about 10% of OGAWA's unrestricted tradable shares from controlling shareholders, a share-transfer event with no stated operational impact.
OGAWA's fund holds less than 1% of Xinghai Tu, a minor investment mentioned only as context for its embodied-intelligence exploration.
